A Phase III, Randomized, Double-blinded Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to Dabrafenib and Placebo as First-line Therapy in Subjects With Unresectable (Stage IIIC) or Metastatic (Stage IV) BRAF V600E/K Mutation-positive Cutaneous Melanoma.

Trial Profile

A Phase III, Randomized, Double-blinded Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to Dabrafenib and Placebo as First-line Therapy in Subjects With Unresectable (Stage IIIC) or Metastatic (Stage IV) BRAF V600E/K Mutation-positive Cutaneous Melanoma.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Dabrafenib (Primary) ; Trametinib (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms COMBI-d
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Nov 2016 Results of retrospective analysis from pooled data of BRF113220, COMBI-d and COMBI-v trials (n=617) published in the Lancet Oncology.
    • 11 Oct 2016 Results of retrospective analysis of patient reported outcomes from 2 phase III trials (COMBI-d and COMBI-v) presented at the 41st European Society for Medical Oncology Congress
    • 11 Oct 2016 Results of a pooled analysis of factors to predict durable benefits with combination of dabrafenib and trametinib, using patient data from BRF113220, COMBI-d and COMBI-v trials (n=617) presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top